Skip to content
DataLookout
Menu

NCT07911683

Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Overall Response Assessment (ORR) by Independent Review Committee Assessment
Timeframe: Up to approximately 15 months

Secondary (5)

Duration of Response (DOR)
ORR by Investigator Assessment
Progression Free Survival (PFS)
Overall Survival (OS)
Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-Mediated Adverse Events (iMAEs)

Arms and interventions

BGB-B2033 MonotherapyExperimental

Participants will receive BGB-B2033 intravenously until progressive disease, unacceptable toxicity, or withdrawal of consent.

Drugs: BGB-B2033